PURPOSE: High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified. PATIENTS AND METHODS: To identify predictive biomarkers of clinical response, sera from patients treated with high-dose IL-2 were collected for analysis using a customized, multiplex antibody-targeted protein array platform that surveyed expression of soluble factors associated with tumor immunobiology. Soluble factors associated with clinical responses were analyzed using a multivariate permutation test, and survival outcomes were determined using Kaplan-Meier and log-rank tests. RESULTS: A training set from 10 patients identified 68 potentially relevant soluble factors that were then tested in an independent validation set of 49 patients. Class comparison revealed a cluster of 11 biomarkers that were associated with therapeutic outcome. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response. In particular, high levels of these proteins were correlated with lack of clinical response and decreased overall survival. CONCLUSION: Serum VEGF and fibronectin are easily measured pretreatment biomarkers that could serve to exclude patients unlikely to respond to IL-2 therapy.
PURPOSE: High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified. PATIENTS AND METHODS: To identify predictive biomarkers of clinical response, sera from patients treated with high-dose IL-2 were collected for analysis using a customized, multiplex antibody-targeted protein array platform that surveyed expression of soluble factors associated with tumor immunobiology. Soluble factors associated with clinical responses were analyzed using a multivariate permutation test, and survival outcomes were determined using Kaplan-Meier and log-rank tests. RESULTS: A training set from 10 patients identified 68 potentially relevant soluble factors that were then tested in an independent validation set of 49 patients. Class comparison revealed a cluster of 11 biomarkers that were associated with therapeutic outcome. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response. In particular, high levels of these proteins were correlated with lack of clinical response and decreased overall survival. CONCLUSION: Serum VEGF and fibronectin are easily measured pretreatment biomarkers that could serve to exclude patients unlikely to respond to IL-2 therapy.
Authors: Melissa P Upton; Robert A Parker; Amanda Youmans; David F McDermott; Michael B Atkins Journal: J Immunother Date: 2005 Sep-Oct Impact factor: 4.456
Authors: Joyce E Ohm; Dmitry I Gabrilovich; Gregory D Sempowski; Ekaterina Kisseleva; Kelly S Parman; Sorena Nadaf; David P Carbone Journal: Blood Date: 2003-02-13 Impact factor: 22.113
Authors: Ena Wang; Lance D Miller; Galen A Ohnmacht; Simone Mocellin; Ainhoa Perez-Diez; David Petersen; Yingdong Zhao; Richard Simon; John I Powell; Esther Asaki; H Richard Alexander; Paul H Duray; Meenhard Herlyn; Nicholas P Restifo; Edison T Liu; Steven A Rosenberg; Francesco M Marincola Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Errol S Wijelath; Jacqueline Murray; Salman Rahman; Yatin Patel; Atsushi Ishida; Kurt Strand; Salim Aziz; Carlos Cardona; William P Hammond; Geoffrey F Savidge; Shahin Rafii; Michael Sobel Journal: Circ Res Date: 2002-07-12 Impact factor: 17.367
Authors: Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi Journal: Cancer J Date: 2012 Mar-Apr Impact factor: 3.360
Authors: José Luis Pérez-Gracia; Alfonso Gúrpide; María Gloria Ruiz-Ilundain; Carlos Alfaro Alegría; Ramon Colomer; Jesús García-Foncillas; Ignacio Melero Bermejo Journal: Clin Transl Oncol Date: 2010-03 Impact factor: 3.405
Authors: Ahmad A Tarhini; Paul Frankel; Kim A Margolin; Scott Christensen; Christopher Ruel; Janice Shipe-Spotloe; David R Gandara; Alice Chen; John M Kirkwood Journal: Clin Cancer Res Date: 2011-08-31 Impact factor: 12.531
Authors: Yulian Mytsyk; Victor Dosenko; Yuriy Borys; Askold Kucher; Katarina Gazdikova; Dietrich Busselberg; Martin Caprnda; Peter Kruzliak; Ammad Ahmad Farooqi; Manyuk Lubov Journal: Int Urol Nephrol Date: 2018-03-16 Impact factor: 2.370
Authors: Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger Journal: Hum Pathol Date: 2009-12-11 Impact factor: 3.466
Authors: Gina Shetty; Georgia M Beasley; Sara Sparks; Michael Barfield; Melanie Masoud; Paul J Mosca; Scott K Pruitt; April K S Salama; Cliburn Chan; Douglas S Tyler; Kent J Weinhold Journal: Ann Surg Oncol Date: 2013-03-02 Impact factor: 5.344
Authors: Martina Sanlorenzo; Igor Vujic; Christian Posch; Akshay Dajee; Adam Yen; Sarasa Kim; Michelle Ashworth; Michael D Rosenblum; Alain Algazi; Simona Osella-Abate; Pietro Quaglino; Adil Daud; Susanna Ortiz-Urda Journal: Cancer Biol Ther Date: 2014-03-20 Impact factor: 4.742